Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution

▤ Summary

Cue Biopharma announced a board transition that includes the resignation of four independent directors and the addition of Daniel Camardo and Viola Meehan. The company says the changes support its move toward a late-stage clinical profile and its broader strategic growth plans. Camardo brings commercial launch and leadership experience, while Meehan adds finance and governance expertise. The company also emphasizes continued expansion of its pipeline and leadership team as it builds operational momentum.

▦ Linked Companies